Protagonist Therapeutics Inc PTGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTGX is a good fit for your portfolio.
News
-
Protagonist Therapeutics Set to Join S&P SmallCap 600
-
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
-
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
-
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
-
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
-
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
Trading Information
- Previous Close Price
- $34.62
- Day Range
- $34.32–34.74
- 52-Week Range
- $13.74–35.90
- Bid/Ask
- $34.56 / $34.81
- Market Cap
- $2.02 Bil
- Volume/Avg
- 162 / 862,991
Key Statistics
- Price/Earnings (Normalized)
- 14.18
- Price/Sales
- 6.59
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 124
- Website
- https://www.protagonist-inc.com
Comparables
Valuation
|
Metric
|
PTGX
|
IMVT
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.18 | — | — |
Price/Book Value | 3.62 | 6.25 | 0.97 |
Price/Sales | 6.59 | — | — |
Price/Cash Flow | 10.84 | — | — |
Price/Earnings
PTGX
IMVT
EQRX
Financial Strength
|
Metric
|
PTGX
|
IMVT
|
EQRX
|
|---|---|---|---|
Quick Ratio | 15.61 | 13.18 | 18.43 |
Current Ratio | 15.72 | 13.70 | 18.78 |
Interest Coverage | — | — | — |
Quick Ratio
PTGX
IMVT
EQRX
Profitability
|
Metric
|
PTGX
|
IMVT
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | 51.28% | −44.70% | −15.72% |
Return on Equity (Normalized) | 56.32% | −49.06% | −16.71% |
Return on Invested Capital (Normalized) | 51.24% | −53.44% | −21.31% |
Return on Assets
PTGX
IMVT
EQRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Prrdfygwt | Sdwk | $636.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ksvnjqbpc | Rgdwmp | $122.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jnxnydwf | Mtxvht | $115.1 Bil | |||
| Moderna Inc
MRNA
| Ctvwpxp | Rwp | $44.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qmfksmjpm | Tffvwjb | $31.3 Bil | |||
| argenx SE ADR
ARGX
| Hfshkqgl | Cldtq | $26.2 Bil | |||
| BioNTech SE ADR
BNTX
| Xgkkxmny | Lsfsg | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pwczcvgq | Dxrqykn | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Swyqblqn | Wcz | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Plqxbxzt | Tcmwqf | $11.7 Bil |